ABCB4 p.Ile299Met
| Predicted by SNAP2: | A: N (61%), C: N (66%), D: D (85%), E: D (80%), F: N (87%), G: D (71%), H: D (80%), K: D (80%), L: N (87%), M: N (72%), N: D (80%), P: D (85%), Q: D (75%), R: D (80%), S: D (66%), T: N (53%), V: N (82%), W: D (66%), Y: D (71%), |
| Predicted by PROVEAN: | A: D, C: D, D: D, E: D, F: N, G: D, H: D, K: D, L: N, M: N, N: D, P: D, Q: D, R: D, S: D, T: D, V: N, W: D, Y: D, |
[switch to compact view]
Comments [show]
None has been submitted yet.
[hide] Identification of residues within the drug-binding... J Biol Chem. 2000 Dec 15;275(50):39272-8. Loo TW, Clarke DM
Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane.
J Biol Chem. 2000 Dec 15;275(50):39272-8., [PMID:11013259]
Abstract [show]
P-glycoprotein (P-gp) can transport a wide variety of cytotoxic compounds that have diverse structures. Therefore, the drug-binding domain of the human multidrug resistance P-gp likely consists of residues from multiple transmembrane (TM) segments. In this study, we completed cysteine-scanning mutagenesis of all the predicted TM segments of P-gp (TMs 1-5 and 7-10) and tested for inhibition by a thiol-reactive substrate (dibromobimane) to identify residues within the drug-binding domain. The activities of 189 mutants were analyzed. Verapamil-stimulated ATPase activities of seven mutants (Y118C and V125C (TM2), S222C (TM4), I306C (TM5), S766C (TM9), and I868C and G872C (TM10)) were inhibited by more than 50% by dibromobimane. The activities of mutants S222C (TM4), I306C (TM5), I868C (TM10), and G872C (TM10), but not that of mutants Y118C (TM2), V125C (TM2), and S776C (TM9), were protected from inhibition by dibromobimane by pretreatment with verapamil, vinblastine, or colchicine. These results and those from previous studies (Loo, T. W. and Clarke, D. M. (1997) J. Biol. Chem. 272, 31945-31948; Loo, T. W. and Clarke, D. M. (1999) J. Biol. Chem. 274, 35388-35392) indicate that the drug-binding domain of P-gp consists of residues in TMs 4, 5, 6, 10, 11, and 12.
Comments [show]
None has been submitted yet.
No. Sentence Comment
177 The mutants L210I, K209E, and I214T in TM4 of mouse mdr3 (31) and I299M (48) and L305A, S, or T in TM5 of human P-gp also changed the substrate specificity of the transporter (49).
X
ABCB4 p.Ile299Met 11013259:177:66
status: NEW